138907-71-8

Basic information

• Product Name: 5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: SALOR-INT L251496-1EA;ETHYL 5-AMINO-1-(4-BROMOPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE;BUTTPARK 87\09-21;5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
• CAS NO: 138907-71-8
• Molecular Formula: C12H12BrN3O2
• Molecular Weight: 310.15
• Mol File: 138907-71-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 423.6 °C at 760 mmHg
• Flash Point: 210 °C
• Appearance: /
• Density: 1.57 g/cm³
• Vapor Pressure: 2.2E-07mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(138907-71-8)
• EPA Substance Registry System: 5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(138907-71-8)

Safety Data

• Hazardous Substances Data: 138907-71-8(Hazardous Substances Data)

Usage

General Description

5-Amino-1-(4-bromo-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester is a chemical compound with the molecular formula C12H12BrN3O2. It is an ethyl ester derivative of 5-amino-1-(4-bromo-phenyl)-1H-pyrazole-4-carboxylic acid. 5-AMINO-1-(4-BROMO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER can be used in organic synthesis and chemical research as a building block or intermediate. Its structural and functional properties make it potentially useful in the development of pharmaceuticals, agrochemicals, and other fine chemicals. The compound's specific uses and applications can vary depending on its synthesis and purity, and it may require further testing and analysis before it can be utilized in specific processes or products.

InChI:InChI=1/C12H12BrN3O2/c1-2-18-12(17)10-7-15-16(11(10)14)9-5-3-8(13)4-6-9/h3-7H,2,14H2,1H3

Upstream product

• 144918-37-6 (E)-ethyl 2-cyano-3-ethoxyacrylate 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 589-21-9 (4-bromophenyl)hydrazine 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 
• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 

Downstream Products

• 1235034-86-2 1-(4-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1235034-87-3 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1235034-88-4 4-(1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenol 
• 72194-27-5 1-(4-bromophenyl)-1H-pyrazol-5-amine 

Relevant articles and documents

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

Discovery of a potent and selective BCL-XLinhibitor with in vivo activity

A-1155463, a highly potent and selective BCL-XLinhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XLbiology as well as a productive lead structure for further optimization.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

In one aspect, the present invention provides for a compound of Formula I; in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.